Elena Fea

1.0k total citations
29 papers, 602 citations indexed

About

Elena Fea is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Elena Fea has authored 29 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 13 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in Elena Fea's work include Colorectal Cancer Treatments and Studies (13 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer Treatment and Pharmacology (8 papers). Elena Fea is often cited by papers focused on Colorectal Cancer Treatments and Studies (13 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Cancer Treatment and Pharmacology (8 papers). Elena Fea collaborates with scholars based in Italy, Sweden and India. Elena Fea's co-authors include Cristina Granetto, Marco Merlano, Ornella Garrone, Ida Colantonio, Gianmauro Numico, Nicola Silvestris, Marcella Occelli, Milena Gasco, Alfredo Falcone and Fotios Loupakis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Elena Fea

28 papers receiving 586 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elena Fea Italy	13	385	182	109	109	84	29	602
J. David Bass United States	12	241 0.6×	179 1.0×	34 0.3×	78 0.7×	33 0.4×	20	637
Matthew Dixon United States	13	189 0.5×	259 1.4×	30 0.3×	34 0.3×	35 0.4×	56	564
Hollis W. Merrick United States	18	256 0.7×	153 0.8×	42 0.4×	34 0.3×	45 0.5×	47	755
Krzysztof Urbański Poland	13	131 0.3×	85 0.5×	83 0.8×	144 1.3×	42 0.5×	56	576
Ida Colantonio Italy	14	267 0.7×	204 1.1×	107 1.0×	109 1.0×	34 0.4×	39	596
Danielle Vicus Canada	18	223 0.6×	89 0.5×	51 0.5×	63 0.6×	44 0.5×	83	1.0k
Caroline Brammer United Kingdom	8	220 0.6×	109 0.6×	64 0.6×	100 0.9×	208 2.5×	14	546
Anne K. Baumgärtner Germany	6	227 0.6×	194 1.1×	34 0.3×	35 0.3×	49 0.6×	9	451
Chung‐Jen Teng Taiwan	12	149 0.4×	127 0.7×	27 0.2×	16 0.1×	94 1.1×	23	461
Nawar Latif United States	14	167 0.4×	75 0.4×	31 0.3×	43 0.4×	26 0.3×	101	774

Countries citing papers authored by Elena Fea

Since Specialization

Citations

This map shows the geographic impact of Elena Fea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elena Fea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elena Fea more than expected).

Fields of papers citing papers by Elena Fea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elena Fea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elena Fea. The network helps show where Elena Fea may publish in the future.

Co-authorship network of co-authors of Elena Fea

This figure shows the co-authorship network connecting the top 25 collaborators of Elena Fea. A scholar is included among the top collaborators of Elena Fea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elena Fea. Elena Fea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laface, Carmelo, et al.. (2025). HCC and Immunotherapy: The Potential Predictive Role of Gut Microbiota and Future Therapeutic Strategies. SHILAP Revista de lepidopterología. 5(1). 9–9.

Numico, Gianmauro, Elena Fea, Ida Colantonio, et al.. (2023). Patients with cancer and hospital admissions: disease trajectory and strategic choices. BMJ Supportive & Palliative Care. 14(e2). e1721–e1724. 2 indexed citations

Ricci, Vincenzo, et al.. (2020). Circulating cytokines and outcome in metastatic colorectal cancer patients treated with regorafenib. World Journal of Gastrointestinal Oncology. 12(3). 301–310. 6 indexed citations

Garrone, Ornella, Nerina Denaro, Fiorella Ruatta, et al.. (2020). Treating patients with cancer amidst the COVID-19 pandemic: experience of a regional hospital in the Piedmont region in northern Italy. Tumori Journal. 106(5). 427–431. 1 indexed citations

Dell’Aquila, Emanuela, Daniele Rossini, Marco Stellato, et al.. (2019). Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): A pooled analisys of TRIBE and TRIBE-2 studies by GONO. Annals of Oncology. 30. v218–v219. 2 indexed citations

Merlano, Marco, Anna Merlotti, Lisa Licitra, et al.. (2018). Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide. Clinical and Translational Radiation Oncology. 12. 47–52. 15 indexed citations

Courthod, Giulia, Alfredo Tartarone, Orazio Caffo, et al.. (2018). Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.. Journal of Clinical Oncology. 36(6_suppl). 209–209. 1 indexed citations

Merlano, Marco, Cristina Granetto, Elena Fea, Vincenzo Ricci, & Ornella Garrone. (2017). Heterogeneity of colon cancer: from bench to bedside. ESMO Open. 2(3). e000218–e000218. 32 indexed citations

Granetto, Cristina, Vincenzo Ricci, Elena Fea, et al.. (2017). Correlation between the prognostic value of tumor-infiltrating lymphocytes (TILS) and sidedness in colorectal cancer (CC) patients (pts). Annals of Oncology. 28. iii94–iii94. 3 indexed citations

10.

Fea, Elena, Ida Colantonio, Nerina Denaro, et al.. (2016). Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 27. iv38–iv38. 2 indexed citations

11.

Numico, Gianmauro, Marcella Occelli, Marco Sicuro, et al.. (2016). Prolonged Drainage and Intrapericardial Bleomycin Administration for Cardiac Tamponade Secondary to Cancer-Related Pericardial Effusion. Medicine. 95(15). e3273–e3273. 20 indexed citations

12.

Masi, Gianluca, Lisa Salvatore, Luca Boni, et al.. (2015). Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Annals of Oncology. 26(4). 724–730. 125 indexed citations

13.

Numico, Gianmauro, Marcella Occelli, Elvio Russi, et al.. (2011). Survival prediction and frequency of anticancer treatment in cancer patients hospitalized due to acute conditions. Role of clinical parameters and PaP score. Supportive Care in Cancer. 19(11). 1823–1830. 16 indexed citations

14.

Numico, Gianmauro, Gianfilippo Bertelli, Erich W. Russi, et al.. (2009). The process of truth disclosure: an assessment of the results of information during the diagnostic phase in patients with cancer. Annals of Oncology. 20(5). 941–945. 49 indexed citations

15.

Masi, Gianluca, Fotios Loupakis, Giacomo Giulio Baldi, et al.. (2008). First-line treatment of metastatic colorectal cancer (MCRC) with folfoxiri (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the G.O.N.O. Group. CINECA IRIS Institutial research information system (University of Pisa). 2 indexed citations

16.

Falcone, Alfredo, Gianluca Masi, Fotios Loupakis, et al.. (2008). FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group. Journal of Clinical Oncology. 26(15_suppl). 4031–4031. 17 indexed citations

17.

Numico, Gianmauro, Elvio Russi, Ida Colantonio, et al.. (2006). Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: A pharmacology-guided schedule. International Journal of Radiation Oncology*Biology*Physics. 66(3). 731–737. 15 indexed citations

18.

Bertelli, Gianfilippo, Giuseppe Arena, Ornella Garrone, et al.. (2005). Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients. Cancer Chemotherapy and Pharmacology. 57(1). 46–51. 17 indexed citations

19.

Numico, Gianmauro, Ornella Garrone, Nicola Silvestris, et al.. (2005). Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer. 103(5). 994–999. 166 indexed citations

20.

Donadio, Michela, Mara Ardine, Alfredo Berruti, et al.. (2003). Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study. Cancer Chemotherapy and Pharmacology. 52(2). 147–152. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact